Physician profile
Jessica Oliver
NPI 1114585940
$233,281.37
in general payments reported to CMS, 2019-2025
20 companies · $176K in 2025
The $176K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,399 · 2022: $1,566 · 2023: $14K · 2024: $41K · 2025: $176K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Honoraria: $55K · Consulting Fee: $27K · Travel and Lodging: $20K · Food and Beverage: $13K · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,278.00 |
| Honoraria | $55,176.00 |
| Consulting Fee | $26,688.00 |
| Travel and Lodging | $20,249.94 |
| Food and Beverage | $12,875.42 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94,924.17 | 2021-2025 | |
| Axsome Therapeutics, INC. | $88,054.27 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $43,799.77 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,259.82 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,224.89 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $859.64 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $757.88 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $756.37 | 2021-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $542.40 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $439.87 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $215.52 | 2023-2025 | Rexulti |
| Indivior INC. | $101.57 | 2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $76.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.01 | 2021 | |
| Corium, LLC | $56.77 | 2021-2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $48.18 | 2021-2023 | Jornay Pm |
| Almatica Pharma LLC | $38.81 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $20.92 | 2025 | Qelbree |
| Eisai INC. | $20.29 | 2021 | |
| Bausch Health US, LLC | $16.01 | 2024 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.